FDA approves Eli Lilly Alzheimer’s diagnosis drug

Eli Lilly (NYSE:LLY) says the Food and Drug Administration approved its Tauvid radioactive diagnostic agent for intravenous injection as the first drug used to help image tau neurofibrillary tangles, a distinctive characteristic of Alzheimer’s disease in the brain.

The approval marks a leap from the current method of detection of tau tangles, which is to study the brains of people who have died.

Eli Lilly’s agent is given to patients intravenously and binds to certain sites in the brain where tau is known to form, and the brain can then be imaged with a PET scan to identify the tangles.

https://seekingalpha.com/news/3578522-fda-approves-eli-lilly-alzheimers-diagnosis-drug